文献速递帕金森病与运动障碍

左旋多巴治疗未控制的帕金森病患者中,儿茶酚-O-甲基转移酶或单胺氧化酶B抑制剂与多巴胺受体激动剂辅助治疗的长期有效性:PD MED随机临床试验

Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2022-01-01

这项在64家神经科和老年科诊所招募500例患者的实用型半析因随机临床试验,比较多巴胺受体激动剂与多巴胺再摄取抑制剂(MAO-B或COMT抑制剂)辅助治疗左旋多巴未控制的运动并发症的长期效果,中位随访4.5年。结果显示多巴胺受体激动剂组与MAO-B和COMT抑制剂联合组PDQ-39活动域评分差异无统计学意义;MAO-B抑制剂组PDQ-39活动域评分和EQ-5D-3L效用评分均优于COMT抑制剂组。

要点

  • 多巴胺受体激动剂组PDQ-39活动域评分较MAO-B和COMT抑制剂联合组好2.4分(95%CI -1.3至6.0分;P=.20),差异无统计学意义。
  • MAO-B抑制剂组PDQ-39活动域评分较COMT抑制剂组好4.2分(95%CI 0.4至7.9分;P=.03)。
  • MAO-B抑制剂组EQ-5D-3L效用评分较COMT抑制剂组好0.05分(95%CI 0.003至0.09分;P=.04)。

核心结论

  • 在左旋多巴治疗未控制的运动并发症帕金森病患者中,COMT抑制剂辅助治疗的患者自评生活质量劣于MAO-B抑制剂或 dopamine 受体激动剂。
  • MAO-B抑制剂产生等效的疾病控制,作者认为这些药物作为辅助治疗可能使用不足。

研究设计与样本

  • 实用型半析因(2×1)随机临床试验,于2001年2月23日至2009年12月15日从64家神经科和老年科诊所(英国62家、捷克共和国1家、俄罗斯1家)招募500例特发性帕金森病伴未控制运动并发症且无痴呆的患者。
  • 采用计算机最小化程序按1:1:1随机分配,数据于2017年至2020年间分析,主要结局为39项帕金森病问卷(PDQ-39)活动域评分和成本效果,采用意向性治疗分析。

主要发现

  • 500例参与者平均(SD)年龄73.0(8.2)岁,314例(62.8%)为男性,中位随访4.5年(范围0-13.3年)。
  • 多巴胺受体激动剂组平均PDQ-39活动域评分较MAO-B和COMT抑制剂联合组好2.4分(95%CI -1.3至6.0分),差异无统计学意义(P=.20)。
  • MAO-B抑制剂组平均PDQ-39活动域评分较COMT抑制剂组好4.2分(95%CI 0.4至7.9分;P=.03),EQ-5D-3L效用评分较COMT抑制剂组好0.05分(95%CI 0.003至0.09分;P=.04)。
  • PDQ-39汇总指数平均差异2.2分(95%CI -0.2至4.5分;P=.07),痴呆风险比(RR)0.70(95%CI 0.47-1.03;P=.07),死亡率RR 0.76(95%CI 0.56-1.03;P=.07),均未达统计学显著。
  • 仅比较多巴胺受体激动剂与MAO-B抑制剂时,结局相似。

关键数值与推荐

  • 主要结局为PDQ-39活动域评分和成本效果。
  • MAO-B抑制剂组PDQ-39活动域评分较COMT抑制剂组好4.2分(95%CI 0.4至7.9分;P=.03)。
  • MAO-B抑制剂组EQ-5D-3L效用评分较COMT抑制剂组好0.05分(95%CI 0.003至0.09分;P=.04)。

临床怎么用

  • 在左旋多巴治疗未控制的运动并发症帕金森病患者中,COMT抑制剂辅助治疗的患者自评生活质量劣于MAO-B抑制剂或 dopaminergic 受体激动剂。
  • MAO-B抑制剂产生等效的疾病控制,作者认为这些药物作为辅助治疗可能使用不足。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Many people with Parkinson disease (PD) develop motor complications that are uncontrolled by levodopa dose adjustment. Among these patients, it is uncertain which drug class is more effective as adjuvant therapy. OBJECTIVE: To compare the long-term effects on patient-rated quality of life of adding a dopamine agonist vs a dopamine reuptake inhibitor (DRI), either a monoamine oxidase type B (MAO-B) inhibitor or a catechol-O-methyltransferase (COMT) inhibitor, to levodopa therapy for the treatment of patients with motor complications of PD. DESIGN, SETTING, AND PARTICIPANTS: This pragmatic semifactorial (2 × 1) randomized clinical trial recruited from 64 neurology and geriatric clinics (62 in the United Kingdom, 1 in the Czech Republic, and 1 in Russia) between February 23, 2001, and December 15, 2009. A total of 500 patients with idiopathic PD who developed uncontrolled motor complications and did not have dementia were randomly assigned on a 1:1:1 basis using a computerized minimization program. Data were analyzed between 2017 and 2020. INTERVENTIONS: Open-label dopamine agonist, MAO-B inhibitor, or COMT inhibitor. MAIN OUTCOMES AND MEASURES: Primary outcomes were scores on the 39-item Parkinson's Disease Questionnaire (PDQ-39) mobility domain and cost-effectiveness. Outcomes were assessed before study entry, at 6 and 12 months after randomization, and annually thereafter. Repeated-measures and log rank analyses were used in an intention-to-treat approach. RESULTS: Among 500 participants, the mean (SD) age was 73.0 (8.2) years; 314 participants (62.8%) were men. Over a median of 4.5 years (range, 0-13.3 years) of follow-up, the participants in the dopamine agonist group had a mean PDQ-39 mobility score that was 2.4 points (95% CI, -1.3 to 6.0 points) better than that of the combined MAO-B and COMT groups; however, this difference was not significant (P=.20). With regard to DRIs, participants in the MAO-B group had mean PDQ-39 mobility scores that were 4.2 points (95% CI, 0.4-7.9 points; P=.03) better than those of the COMT group and EuroQol 5-dimension 3-level (EQ-5D-3L) utility scores that were 0.05 points (95% CI, 0.003-0.09 points; P=.04) better than the COMT group. Nonsignificant improvements were found in the PDQ-39 summary index (mean difference, 2.2 points; 95% CI, -0.2 to 4.5 points; P=.07) along with nonsignificant reductions in dementia (rate ratio [RR], 0.70; 95% CI, 0.47-1.03; P = .07) and mortality (RR, 0.76; 95% CI, 0.56-1.03; P=.07). When dopamine agonists were compared with MAO-B inhibitors only, the outcomes were similar. CONCLUSIONS AND RELEVANCE: In this study, patient-rated quality of life was inferior when COMT inhibitors were used as adjuvant treatment compared with MAO-B inhibitors or dopamine agonists among people with PD who experienced motor complications that were uncontrolled by levodopa therapy. The MAO-B inhibitors produced equivalent disease control, suggesting that these agents may be underused as adjuvant therapy. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN69812316; EU Clinical Trials Register Identifier: 2005-001813-16.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Gray R, Patel S, Ives N, et al. Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial. JAMA Neurol. 2022. PMID: 34962574. doi:10.1001/jamaneurol.2021.4736

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。